Laurion Capital Management’s BridgeBio Oncology BBOT Stock Holding History

Laurion Capital Management’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.3M	Buy	2,002,701 +80,045	+4%	+$668K	0.39%	68
2026 Q1	$17.2M	Buy	1,922,656 +457,718	+31%	+$4.91M	0.75%	27
2025 Q4	$18.3M	Buy	1,464,938 +419,138	+40%	+$5.08M	0.68%	31
2025 Q3	$12.1M	Buy	1,045,800 +745,800	+249%	+$7.77M	0.21%	88
2025 Q2	$3.19M	Hold	300,000	–	–	0.06%	143
2025 Q1	$3.39M	Hold	300,000	–	–	0.09%	127
2024 Q4	$3.15M	Hold	300,000	–	–	0.06%	167
2024 Q3	$3.13M	Hold	300,000	–	–	0.04%	130
2024 Q2	$3.07M	Hold	300,000	–	–	0.04%	185
2024 Q1	$3.1M	Buy	+300,000	New	+$3.11M	0.03%	299

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Laurion Capital Management's BBOT Position: Q2 2026 in Review

Laurion Capital Management increased its BridgeBio Oncology (BBOT) stake by 4.2% in Q2 2026, buying an estimated $668K and bringing the position to 2,002,701 shares worth $15.3M. The position accounts for 0.39% of the portfolio, ranked #68.

Laurion Capital Management first reported a position in BBOT in Q1 2024 and has held it in 10 quarters since. The position peaked at $18.3M in Q4 2025. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

Laurion Capital Management held 2,002,701 shares of BridgeBio Oncology worth $15.3M as of Q2 2026.
Laurion Capital Management bought 80,045 BridgeBio Oncology shares in Q2 2026, an estimated $668K.
BridgeBio Oncology made up 0.39% of Laurion Capital Management's portfolio in Q2 2026, its #68 holding.
Laurion Capital Management first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 10 quarters since.
Laurion Capital Management's BridgeBio Oncology position peaked at $18.3M in Q4 2025.
65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.